CBX-250

N/A

Report date: 2026/03/17 20:00:15
First In Class

Base Information

Drug NameCBX-250
Drug Alias NameCBX-250
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionHuman leukocyte antigen modulatorsCathepsin G modulators
TargetsHuman leukocyte antigenCathepsin G
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrossbow Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCrossbow Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A